Distinct Roles for Sarcolemmal and Mitochondrial Adenosine Triphosphate–sensitive Potassium Channels in Isoflurane-induced Protection against Oxidative Stress

Jasna Marinovic, M.D.,* Zejko J. Bosnjak, Ph.D.,† Anna Stadnicka, Ph.D.‡

Background: Cardiac preconditioning, including that induced by halogenated anesthetics, is an innate protective mechanism against ischemia–reperfusion injury. The adenosine triphosphate–sensitive potassium (KATP) channels are considered essential in preconditioning mechanism. However, it is unclear whether KATP channels are triggers initiating the preconditioning signaling, and/or effectors responsible for the cardioprotective memory and activated during ischemia–reperfusion.

Methods: Adult rat cardiomyocytes were exposed to oxidative stress with 200 μM H2O2 and 100 μM FeSO4. Myocyte survival was determined based on morphologic characteristics and trypan blue exclusion. To induce preconditioning, the myocytes were pretreated with isoflurane. The involvement of sarcolemmal and mitochondrial KATP channels was investigated using specific inhibitors HMR-1098 and 5-hydroxydecanoic acid. Data are expressed as mean ± SD.

Results: Oxidative stress induced cell death in 47 ± 14% of myocytes. Pretreatment with isoflurane attenuated this effect to 26 ± 8%. Blockade of the sarcolemmal KATP channels abolished the protection by isoflurane pretreatment when HMR-1098 was applied throughout the experiment (50 ± 21%) or only during oxidative stress (50 ± 12%), but not when applied during isoflurane pretreatment (29 ± 13%). Inhibition of the mitochondrial KATP channels abolished cardioprotection irrespective of the timing of 5-hydroxydecanoic acid application. Cell death was 42 ± 23, 45 ± 23, and 46 ± 22% when 5-hydroxydecanoic acid was applied throughout the experiment, only during isoflurane pretreatment, or only during oxidative stress, respectively.

Conclusion: The authors conclude that both sarcolemmal and mitochondrial KATP channels play essential and distinct roles in protection afforded by isoflurane. Sarcolemmal KATP channel seems to act as an effector of preconditioning, whereas mitochondrial KATP channel plays a dual role as a trigger and an effector.

CARDIAC preconditioning is an innate protective mechanism against injury by ischemia and reperfusion.1 In addition to the extent of cardioprotection, one of the most remarkable characteristics of preconditioning is the memory phase, when the cardioprotective effects persist despite removal of the preconditioning stimulus. To date, numerous studies have investigated the mechanism of preconditioning, and many crucial components underlying cardioprotection have been identified. Adenosine triphosphate–sensitive potassium (KATP) channels have long been considered essential components of cardioprotection by ischemic and pharmacologic preconditioning. Acting as metabolic sensors, regulated by intracellular metabolic factors such as adenosine triphosphate, adenosine diphosphate, and cytosolic pH, they are attractive candidates as the major contributors to the mechanism of cardioprotection. Their critical role for cardiac preconditioning, including that induced by halogenated anesthetics, has been demonstrated in a number of studies.2–5

There are two populations of KATP channels in cardiac myocytes: the mitochondrial (mitoKATP) channel located in the inner mitochondrial membrane and the sarcolemmal (sarcKATP) channel located in the plasma membrane. Initially, before discovery of mitoKATP channels, the cardioprotective effects of preconditioning were attributed to the sarcKATP channels.2 The protective effects of KATP channel opening were ascribed to action potential shortening and the resulting decrease in Ca2+ overload during ischemia and reperfusion.6 However, later studies demonstrated that cardioprotective actions of KATP channel openers are independent of the action potential shortening.7,8 After a more recent discovery of the mitoKATP channels in the inner mitochondrial membrane and development of selective mito and sarcKATP channel inhibitors, evidence suggested that mitoKATP channels rather than the sarcKATP channels play a more important role in cardioprotection.9 HMR-1098, a specific inhibitor of sarcKATP channel, has often failed to abolish protection by ischemic and pharmacologic preconditioning, whereas cardioprotection was elicited by the mitoKATP channel activator diazoxide.4,10 This led to a widespread opinion that cardioprotective effects of preconditioning depend mostly on the mitoKATP channel. However, some of the recent studies that involved the use of sarcKATP-specific inhibitors and genetic models of disrupted or knocked-out sarcKATP channel subunits indicated that the role of sarcKATP channel in cardioprotection should not be ignored.11–13

The involvement of sarcKATP channels in cardioprotection by anesthetic-induced preconditioning (APC) was demonstrated in a limited number of studies.14,15 More studies demonstrated a predominant role of the mitoKATP channels in APC, while finding no apparent involvement of the sarcKATP channel.16–19 In addition to the conflicting results regarding the relative importance of sarcKATP and mitoKATP channels, their specific roles remain unclear. It is uncertain whether they are triggers, important for initiating the preconditioning signaling.

* Research Fellow, † Professor and Vice Chairman for Research of Anesthesiology, ‡ Associate Professor of Anesthesiology.

Received from the Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin. Submitted for publication November 10, 2005. Accepted for publication April 3, 2006. Supported in part by grant Nos. HL 034708 (to Dr. Bosnjak) and PO1 GM060730 (to Dr. Bosnjak) from the National Institutes of Health, Bethesda, Maryland.

Address correspondence to Dr. Stadnicka: Department of Anesthesiology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226; astadnicka@mccw.edu. Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org.
cascade, or effectors, the endpoints of the preconditioning cascade, responsible for the cardioprotection memory and activated during ischemia–reperfusion.\textsuperscript{3,5,20}

Therefore, the goal of the current study was to test whether sarcK\textsubscript{ATP} and mitoK\textsubscript{ATP} channels contribute to isoflurane preconditioning and to investigate their exact role in protection afforded by isoflurane. We found that both sarcK\textsubscript{ATP} and mitoK\textsubscript{ATP} channels are essential components of APC and that each channel plays a distinct role: The sarcK\textsubscript{ATP} channel acts as an effector, whereas the mitoK\textsubscript{ATP} channel acts both as a trigger and as an effector of preconditioning.

Materials and Methods

The animal use and experimental protocols of this study were approved by the Animal Use and Care Committee of the Medical College of Wisconsin, Milwaukee, Wisconsin.

Cell Isolation

Ventricular myocytes were isolated from hearts of adult male Wistar rats (150–250 g) by enzymatic dissociation. The rats were injected with heparin (1,000 U intraperitoneally) and anesthetized with thiobutabarbital (Inactin, 100 mg/kg intraperitoneally; Sigma-Aldrich, St. Louis, MO). After thoracotomy, the hearts were excised, mounted on a Langendorff apparatus and retrogradely perfused with heparinized Joklik medium (Gibco BRI; Invitrogen, Grand Island, NY) at the flow rate of 7 ml/min. After the blood had been washed out, the perfusate was replaced with an enzyme solution containing Joklik medium supplemented with 0.5 mg/ml collagenase type II (Invitrogen, Carlsberg, CA), 0.25 mg/ml protease XIV (Sigma-Aldrich), and 1 mg/ml bovine serum albumin (Serologicals, Kankakee, IL) at pH 7.23. All solutions were continuously gassed with a mixture of 95% O\textsubscript{2}-5% CO\textsubscript{2} and were kept at 37°C. After 25 min of enzyme digestion, the ventricles were excised, minced, and incubated in the enzyme solution for additional 8–10 min in a shaker bath at 37°C. The cell suspension was filtered through 200 μm mesh and centrifuged. The cell pellet was then washed twice in modified Tyrode solution (132 mM NaCl, 10 mM HEPES, 5 mM glucose, 5 mM KCl, 1 mM CaCl\textsubscript{2}, and 1.2 mM MgCl\textsubscript{2}, adjusted to pH 7.4). Cells that were rod-shaped and excluded trypan blue were considered living\textsuperscript{21} and were counted. The counting time was monitored and was kept uniform in all experiments (10 min). In each experiment, approximately 250 myocytes were counted.

The average concentration of isoflurane used in this study was 0.4% (Sigma-Aldrich), for 2 min followed by a dye washout with glucose-free Tyrode solution (132 mM NaCl, 10 mM HEPES, 5 mM KCl, 1 mM CaCl\textsubscript{2}, and 1.2 mM MgCl\textsubscript{2}, adjusted to pH 7.4). Cells that were rod-shaped and excluded trypan blue were considered living\textsuperscript{21} and were counted. The counting time was monitored and was kept uniform in all experiments (10 min). In each experiment, approximately 250 myocytes were counted.

After cell counting, perfusion with glucose-free Tyrode solution was started. Thirty minutes into the experiment, the myocytes were exposed to oxidative stress by perfusion with 200 μM H\textsubscript{2}O\textsubscript{2} and 100 μM FeSO\textsubscript{4}·7H\textsubscript{2}O (both from Sigma-Aldrich) for 17 min. The mixture of H\textsubscript{2}O\textsubscript{2} and Fe\textsuperscript{2+} yields a highly reactive hydroxyl radical (OH\textsuperscript{-}) via the Fenton reaction.\textsuperscript{22} The 17-min duration was chosen because it was optimal for damaging approximately 50% of myocytes. After oxidative stress, the myocytes were reperfused with glucose-free Tyrode solution for another 20 min and stained with trypan blue, after which the remaining living cells were counted. The percentage of cell death was calculated from the cell count before and after oxidative stress. The location of the myocytes was monitored using a chamber bottom with a labeled grid. This enabled counting of the same myocytes before and after oxidative stress.

The time between cell counts before and after stress was exactly 67 min in all experiments. In the experimental groups that underwent APC, the myocytes were exposed to isoflurane for 20 min and 5 min anesthetic washout before oxidative stress. To investigate the effects of the sarcK\textsubscript{ATP} and mitoK\textsubscript{ATP} channels on cell survival, the specific inhibitor HMR-1098 (50 μM; a gift from Aventis Pharma, Frankfurt am Main, Germany) or 5-hydroxydecanoic acid (5-HD, 200 μM; Sigma-Aldrich, St. Louis, MO) was added to the superfusing solution at different time points. In all experimental groups, n indicates the number of animals. The protocols for all experimental groups are illustrated in figure 1.

Drugs

Isoflurane (Abbott Laboratories, North Chicago, IL) was dispersed in glucose-free Tyrode solution by sonication and delivered to cardiomyocytes from the airtight glass syringes. At the end of each experiment, samples of isoflurane-containing solution were collected from the chamber, and the concentrations of isoflurane were analyzed by gas chromatography (Shimadzu, Kyoto, Japan). The average concentration of isoflurane used in this study was 0.51 ± 0.09 ms, equivalent to 1.2 vol% at 22°C. The 5-min washout period was sufficient to remove all isoflurane from the chamber as confirmed by isoflurane measurements after the washout. HMR-1098 and 5-HD were kept as stock solution in double-distilled water. All stock solutions were diluted to required con-
concentration in the superfusing buffer immediately before application.

**Statistical Analysis**

Results are expressed as mean ± SD. Data were analyzed using Origin 7 software (OriginLab, Northampton, MA). Statistical analysis was performed using one-way analysis of variance with Scheffé post hoc test. Differences were considered significant when the two-tailed P value was less than 0.05.

**Results**

**Isoflurane Protects Isolated Cardiomyocytes from Oxidative Stress**

Oxidative stress was used to mimic the reperfusion injury and investigate isoflurane-induced myocyte protection. In the time control group, 67 min of perfusion with glucose-free Tyrode solution had no significant effect on cell death (7 ± 5%, n = 5; fig. 2, TC group). During exposure to 200 μM H₂O₂ and 100 μM FeSO₄, some of the otherwise nonbeating cardiomyocytes started contracting, which resulted in cell hypercontraction and death in 47 ± 14% of cardiomyocytes (n = 11, stress group). When cardiomyocytes were pretreated with isoflurane before oxidative stress (APC group), cell death was markedly attenuated to 26 ± 8% (P < 0.05, n = 10). These results demonstrated that in vitro pretreatment with isoflurane protects the cardiomyocytes from damage by oxidative stress.

**Sarcolemmal Kₐtp Channel Blockade during Oxidative Stress, but Not during Isoflurane Pretreatment, Abolishes Protection by Isoflurane**

To investigate the role of sarcolemmal Kₐtp channels in protection by isoflurane, the selective sarcolemmal Kₐtp channel inhibitor HMR-1098 was used. HMR-1098 (50 μM) applied throughout the experiment had no effect on myocyte death in the time control group (5 ± 3%; n = 6; fig. 3A, TC + HMR group). Application of HMR-1098 did not potentiate the deleterious effects of oxidative stress, and cell damage in this group was 48 ± 13% (n = 9; fig. 3A, stress + HMR group). However, inhibition of the sarcolemmal Kₐtp channel completely abolished the protective effects of isoflurane, and cell death after isoflurane pretreatment in the presence of HMR-1098 was 50 ± 21% (n = 9; APC + HMR group).

To determine the exact time period in which the sarcolemmal Kₐtp channel activation is protective, HMR-1098 was applied only during isoflurane exposure, the cardioprotective effects of isoflurane were still present and cell damage by oxidative stress was lower than without isoflurane pretreatment (29 ± 13%, n = 7; fig. 3B, APC + HMR ISO group). However, when HMR-1098 was applied only during oxidative stress, the protective effects of isoflurane were completely abolished and cell death was 50 ± 12% (n = 7; APC + HMR stress group). These results show that activation of the sarcolemmal Kₐtp channel during the stress period is necessary for isoflurane-induced myocyte protection.
Mitochondrial $K_{ATP}$ Channel Inhibition during Both Isoflurane Pretreatment and Oxidative Stress Abolishes Isoflurane-induced Protection

To assess contribution of the mitoK$_{ATP}$ channel to isoflurane-induced protection against oxidative stress, 5-HD (200 μM), a selective inhibitor of the mitoK$_{ATP}$ channels, was used. 5-HD was applied either throughout the experiment or during specific parts of the experiment as described previously. 5-HD did not affect cell damage in the time control (TC + HMR). All values were significantly different versus TC + HMR group. (B) Isoflurane-induced protection (APC vs. stress) was abolished when HMR-1098 was applied during the stress period (APC + HMR$_{stress}$), but not during isoflurane pretreatment (APC + HMR$_{pre}$). * $P < 0.05$ versus stress and APC + HMR$_{stress}$.

Discussion

In this study, freshly isolated adult cardiomyocytes were used to investigate specific roles of sarcK$_{ATP}$ and mitoK$_{ATP}$ channels in cardioprotective effects of APC. It was found that both sarcK$_{ATP}$ and mitoK$_{ATP}$ channels are essential for the protection of myocytes from damage by oxidative stress because their inhibition completely abolished the protective effects of isoflurane preconditioning. Specifically, activation of the sarcK$_{ATP}$ channel was required for the cardioprotective effects of APC during the stress period but not during the preconditioning period. In contrast, activation of mitoK$_{ATP}$ channel was found to be necessary during both isoflurane preconditioning and during exposure to oxidative stress. From these results, it seems that although activation of both channels is important for the cardioprotective effects of preconditioning, each channel plays a distinct role: The

Fig. 3. Activation of sarcolemmal adenosine triphosphate–sensitive potassium channel during oxidative stress, but not during isoflurane pretreatment, is essential for the protective effects of isoflurane preconditioning. (A) Protection by isoflurane (APC vs. stress) was abolished in the presence of HMR-1098 (APC + HMR), whereas blockade of sarcolemmal adenosine triphosphate–sensitive potassium channel had no effect on cell damage by oxidative stress (stress + HMR) or cell death in time control (TC + HMR). * $P < 0.05$ versus stress, stress + HMR, and APC + HMR. All values were significantly different versus TC + HMR group. (B) Isoflurane-induced protection (APC vs. stress) was abolished when HMR-1098 was applied during the stress period (APC + HMR$_{stress}$), but not during isoflurane pretreatment (APC + HMR$_{pre}$). * $P < 0.05$ versus stress and APC + HMR$_{stress}$.

Fig. 4. Activation of mitochondrial adenosine triphosphate–sensitive potassium channel is important during both preconditioning by isoflurane and exposure to oxidative stress. (A) Myocyte protection by isoflurane (APC vs. stress) was abolished in the presence of 5-hydroxydecanoic acid (APC + 5-HD). 5-HD alone did not affect cell death in nonpreconditioned myocytes (stress + 5-HD) or in time control (TC + 5-HD). * $P < 0.05$ versus stress, stress + 5-HD, and APC + 5-HD. All values were significantly different versus TC + 5-HD. (B) Blockade of mitochondrial adenosine triphosphate–sensitive potassium channel during both isoflurane preconditioning (APC + 5-HD$_{pre}$) and oxidative stress (APC + 5-HD$_{stress}$) completely abolished isoflurane-induced protection. * $P < 0.05$ versus stress, APC + 5-HD$_{pre}$, and APC + 5-HD$_{stress}$.
The sarcK<sub>ATP</sub> channel acts as an effector, whereas the mitoK<sub>ATP</sub> channel plays a dual role as a trigger and an effector.

In our study, we found that isoflurane protects isolated cardiomyocytes from oxidative stress via both sarcK<sub>ATP</sub> and mitoK<sub>ATP</sub> channel activation, because channel inhibition by HMR-1098 and 5-HD, respectively, abolished cardioprotective effects of APC. Similar results were reported by Toller et al., who demonstrated in a dog model in vivo that infarct size reduction achieved by desflurane preconditioning is abolished in the presence of HMR-1098 and 5-HD. Further, using the same inhibitors, both channels were found to mediate ketamine-induced protection of the force of contraction of human right atrial trabeculae during hypoxia and reoxygenation. In contrast to these studies that demonstrated an equally important role for both sarcK<sub>ATP</sub> and mitoK<sub>ATP</sub> channels, there are studies that demonstrate a more significant role of the mitoK<sub>ATP</sub> channels. For example, Zaugg et al. found that mitoK<sub>ATP</sub> channel inhibition by 5-HD, but not sarcK<sub>ATP</sub> channel inhibition by HMR-1098, completely abolished the cardioprotective effects of isoflurane and sevoflurane in isolated adult rat cardiomyocytes exposed to ischemia. Similarly, Uecker et al. showed that 5-HD completely blocked the cardioprotection by ischemic or isoflurane-induced preconditioning in isolated perfused rat hearts, whereas HMR-1098 had no effect. MitoK<sub>ATP</sub> activation was found to be essential, whereas sarcK<sub>ATP</sub> channel was found to play no role or have only a partial role in desflurane- and sevoflurane-induced preconditioning of isolated human right atria, respectively.

Pronounced differences in findings from these studies that investigated the role of the sarcK<sub>ATP</sub> channel in APC may result from differences in the experimental models used (isolated cardiomyocytes, isolated hearts, atrial trabeculae, in vivo preparation). There are also differences in the insults on the heart (ischemia and reperfusion in vivo, simulated ischemia without reperfusion, hypoxia, oxidative stress, metabolic inhibition). Moreover, the measured endpoints of cardiac injury also differ (cell death and infarcted area vs. functional parameters such as developed force of contraction). Finally, there are differences in the time and duration of application of pharmacologic inhibitors (application during preconditioning stimulus vs. stress period). In our preparation, the timing of application of HMR-1098, but not of 5-HD, was found to be crucial. If HMR-1098 was applied only during the preconditioning stimulus period (isoflurane exposure), cytoprotection was still present, but when HMR-1098 was applied during oxidative stress, cytoprotection was abolished. Therefore, in evaluating the studies that test the role of the sarcK<sub>ATP</sub> channel in preconditioning, it is important to consider the timing of application of the inhibitors. Further, the endpoint variable used to evaluate the myocardial injury is also an important factor. For example, the sarcK<sub>ATP</sub> channel was found not to have a role in the infarct size reduction by adenosine-enhanced ischemic preconditioning, but it was important for the improvement of functional recovery. In the same study, the mitoK<sub>ATP</sub> channel had effect primarily on the infarct size without affecting the functional recovery. Another important condition is the type of insult. Both sarc and mitoK<sub>ATP</sub> channels were shown to have distinct roles in ischemia-reperfusion injury. Activation of the mitoK<sub>ATP</sub> channel mediates the phorbol 12-myristate 13-acetate-induced protection against cell death during chemically induced hypoxia, but not during reoxygenation. In contrast, activation of the sarcK<sub>ATP</sub> channel was protective only during reoxygenation. Therefore, it is possible that if only hypoxia is used as an insult, involvement of the sarcK<sub>ATP</sub> channel in protection against ischemia-reperfusion injury can be overlooked. In addition, the effectiveness of the inhibitors can be altered during application of certain insults. For example, HMR-1098 was found to be ineffective in blocking the sarcK<sub>ATP</sub> currents during metabolic inhibition by NaCN and iodoacetate. This may also explain the often reported lack of HMR-1098 effects on the cardioprotection by ischemic and pharmacologic preconditioning.

One of the most remarkable characteristics of the preconditioning phenomenon is the memory phase, when cardioprotection persists despite withdrawal of the preconditioning stimulus (such as anesthetic in APC). In the complex mechanism of preconditioning, one key element of the preconditioning pathway is triggers, activated during preconditioning stimulus and responsible for initiating the downstream signaling cascade. Another key component is the effectors, which are at the end of the preconditioning signaling pathway and are directly responsible for cardioprotective effects of preconditioning during the memory phase. Some of the identified triggers are Gi-coupled receptors, such as adenosine receptors and a small burst of reactive oxygen species. The downstream signaling cascade includes activation of intracellular kinases, with protein kinase C playing a central role. Kinase activation results in phosphorylation and priming of the effectors and may potentially result in establishing the cardioprotection memory. Both sarcK<sub>ATP</sub> and mitoK<sub>ATP</sub> channels have been implicated as triggers and effectors of preconditioning, but studies have yielded controversial results. In our study, application of HMR-1098 during the stress phase, but not during the preconditioning phase, completely abrogated cardioprotective effects of APC. This suggests that the sarcK<sub>ATP</sub> channel acts as an effector, but not as a trigger of APC, being activated and acting protectively only during the memory phase. These results support our previous studies, which demonstrated that opening of the sarcK<sub>ATP</sub> channel is potentiated during the memory phase of APC and that protein kinase C plays a role in this process.
this effect.\textsuperscript{27} In the current study, application of 5-HD during both the preconditioning phase and the stress phase reversed cardioprotective effects of APC to the same extent, indicating that mitoK\textsubscript{ATP} channel acts as both trigger and effector. The findings were similar to those of Fryer et al.\textsuperscript{28} who demonstrated that the mitoK\textsubscript{ATP} channel acts as both trigger and effector of preconditioning by ischemia, because 5-HD administration before or after the preconditioning phase completely abolished cardioprotection in the rat hearts. In contrast, Pain et al.\textsuperscript{29} demonstrated that the mitoK\textsubscript{ATP} channel acts only as a trigger of ischemic preconditioning in isolated rabbit hearts. Similarly, the mitoK\textsubscript{ATP} channel opening was found to trigger ischemia-induced preconditioning of rabbit hearts by generating reactive oxygen species.\textsuperscript{30} Interestingly, the mitoK\textsubscript{ATP} channel was found to be an effector, but not a trigger, whereas the sarcK\textsubscript{ATP} channel was shown to act as a trigger of the delayed cardioprotection by opioid-induced preconditioning in rats.\textsuperscript{31} Furthermore, the role of the sarcK\textsubscript{ATP} channel as a trigger was demonstrated in the delayed ischemic preconditioning of the rat heart.\textsuperscript{32} However, these studies investigated the delayed phase of preconditioning 24 h after the preconditioning stimulus, whereas our study was focused on the early phase of preconditioning.

The role of the mitoK\textsubscript{ATP} channel as both a trigger and an effector and the role of the sarcK\textsubscript{ATP} channel as the effector of preconditioning could be explained by the following sequence of events. Exposure to isoflurane can directly activate mitoK\textsubscript{ATP} channels.\textsuperscript{33} Opening of the mitoK\textsubscript{ATP} channel results in changes in the mitochondrial bioenergetics, which may result in a small burst of reactive oxygen species,\textsuperscript{29} that can further affect mitochondrial bioenergetics and activate cytosolic mediators such as protein kinase C.\textsuperscript{34–37} Activated protein kinase C translocates to the sarclemma and can then phosphorylate the sarcK\textsubscript{ATP} channel and sensitize it to opening.\textsuperscript{27,38} The primed sarcK\textsubscript{ATP} channel opens sooner and/or more during subsequent metabolic stress (ischemia–reperfusion, oxidative stress, metabolic inhibition, and others), resulting in greater K\textsuperscript{+} efflux, a more rapid repolarization of the cell membrane, and action potential shortening with subsequent contractile failure, which may thereby decrease cytosolic Ca\textsuperscript{2+} loading during ischemia–reperfusion.\textsuperscript{12,13,39} A similar sequence of events occurs in quiescent cardiomyocytes, where sarcK\textsubscript{ATP} channel opening prevents diastolic depolarization of the cell membrane and decreases Ca\textsuperscript{2+} loading.\textsuperscript{40} This can reduce or prevent mitochondrial Ca\textsuperscript{2+} overloading, a major trigger of the cell death pathway.\textsuperscript{41} The mitoK\textsubscript{ATP} channel can also open during ischemia–reperfusion, which may result in depolarization of the inner mitochondrial membrane and thus further decrease driving force for the mitochondrial Ca\textsuperscript{2+} entry and loading during ischemia–reperfusion.\textsuperscript{42} Evidence that pretreatment with the mitoK\textsubscript{ATP} channel opener diazoxide causes early activation of the sarcK\textsubscript{ATP} channel during metabolic inhibition and protects the cells from Ca\textsuperscript{2+} loading via indirect mechanism supports in part such a sequence of events.\textsuperscript{39} From ours as well as other studies, it seems that both the sarcK\textsubscript{ATP} and mitoK\textsubscript{ATP} channel are crucial components of cardioprotection that can interact and potentiate each other’s protective effects. For example, Tanno et al.\textsuperscript{43} showed that HMR-1098 can partially block the protection of isolated rabbit hearts from ischemia–reperfusion injury induced by diazoxide. In the same study, 5-HD completely abolished the cardioprotective effects of pretreatment with a low-dose pinacidil (10 μM) that is considered to open primarily sarcK\textsubscript{ATP} channels but not mitoK\textsubscript{ATP} channels.

It is important to acknowledge some limitations of our study. This study relies on specificity of pharmacologic openers and blockers of the sarcK\textsubscript{ATP} and mitoK\textsubscript{ATP} channels. For example, both 5-HD and diazoxide were shown to have the mitoK\textsubscript{ATP} channel-independent effects in mitochondria,\textsuperscript{44} and we cannot exclude the possibility that abolishment of APC by 5-HD in our study could have been due to the nonspecific effects. In addition, certain limitations are inherent to all in vitro models, including the isolated myocyte model. Disaggregated myocytes are in an artificial environment that is different from that in the whole organ, and in vitro conditions cannot replicate all of the complexity of the in vivo setting. However, one advantage of our model, which contains only myocytes without the presence of other cell types, is that we are able to isolate the effects of drugs (isoflurane, the channel inhibitors) on the cardiomyocytes without vascular and neuronal influences. Also, although the use of oxidative stress does not strictly mimic the conditions during ischemia–reperfusion, both H\textsubscript{2}O\textsubscript{2} and OH\textsuperscript{-} were shown to be a relevant component of ischemia–reperfusion injury in vivo. Therefore, keeping in mind the limitations of the isolated myocyte model, this model might still provide information relevant to the in vivo setting.

From our results, we conclude that both the sarcK\textsubscript{ATP} and the mitoK\textsubscript{ATP} channel play essential and distinct roles in APC in rat heart. The sarcK\textsubscript{ATP} channel acts as an effector of anesthetic preconditioning, whereas the mitoK\textsubscript{ATP} channel plays a dual role as a trigger and an effector.

The authors give special thanks to Martin Bienengraeber, Ph.D. (Assistant Professor, Departments of Anesthesiology and Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin), for helpful discussions. The authors also thank Mary Ziebell (Research Technologist, Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin) for isoflurane measurements.

References


Anesthesiology, V 105, No 1, Jul 2006.

Copyright © by the American Society of Anesthesiologists. Unauthorized reproduction of this article is prohibited.
channels: Mechanism of desflurane-induced cardioprotection. ANESTHESIOLOGY 1997; 87: 561–70


7. Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994; 89:1709–75


17. Zuecker M, Li S, Gramppe T, Pasch T, Schaub MC. Volatile anesthetic mimics cardiac preconditioning by priming the activation of mitochondrial KATP channels via multiple signaling pathways. ANESTHESIOLOGY 2002; 97:4–14


30. Tanoue M, Miura T, Tsuchida A, Miki T, Nishino Y, Ohnuma Y, Shimamoto K. Contribution of both the sarcolemmal K(ATP) and mitochondrial K(ATP) channels to the acute and long-term atrial inotropic effects of diazoxide and 5-hydroxydecanoic acid in the heart. J Physiol (Lond) 2002; 542:753–41